INmune Bio, Inc. (INMB)
1.275
+0.06
(+5.37%)
USD |
NASDAQ |
Jun 11, 16:00
1.26
-0.02
(-1.18%)
After-Hours: 18:28
INmune Bio Enterprise Value : 12.32M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 12.32M |
| June 09, 2026 | 12.59M |
| June 08, 2026 | 13.12M |
| June 05, 2026 | 13.65M |
| June 04, 2026 | 16.04M |
| June 03, 2026 | 15.24M |
| June 02, 2026 | 17.90M |
| June 01, 2026 | 17.11M |
| May 29, 2026 | 17.64M |
| May 28, 2026 | 17.90M |
| May 27, 2026 | 17.37M |
| May 26, 2026 | 18.17M |
| May 22, 2026 | 18.70M |
| May 21, 2026 | 18.43M |
| May 20, 2026 | 17.64M |
| May 19, 2026 | 17.64M |
| May 18, 2026 | 19.76M |
| May 15, 2026 | 21.36M |
| May 14, 2026 | 24.82M |
| May 13, 2026 | 18.97M |
| May 12, 2026 | 17.11M |
| May 11, 2026 | 16.04M |
| May 08, 2026 | 18.17M |
| May 07, 2026 | 18.17M |
| May 06, 2026 | 20.56M |
| Date | Value |
|---|---|
| May 05, 2026 | 21.09M |
| May 04, 2026 | 19.50M |
| May 01, 2026 | 20.30M |
| April 30, 2026 | 18.17M |
| April 29, 2026 | 15.51M |
| April 28, 2026 | 17.37M |
| April 27, 2026 | 19.23M |
| April 24, 2026 | 17.11M |
| April 23, 2026 | 16.84M |
| April 22, 2026 | 18.17M |
| April 21, 2026 | 16.57M |
| April 20, 2026 | 19.76M |
| April 17, 2026 | 18.70M |
| April 16, 2026 | 15.78M |
| April 15, 2026 | 15.24M |
| April 14, 2026 | 13.65M |
| April 13, 2026 | 13.12M |
| April 10, 2026 | 11.52M |
| April 09, 2026 | 14.18M |
| April 08, 2026 | 14.45M |
| April 07, 2026 | 13.92M |
| April 06, 2026 | 12.85M |
| April 02, 2026 | 12.32M |
| April 01, 2026 | 12.85M |
| March 31, 2026 | 10.19M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sangamo Therapeutics, Inc. | 53.47M |
| Arrowhead Pharmaceuticals, Inc. | 9.517B |
| Oncolytics Biotech, Inc. | 87.93M |
| Sarepta Therapeutics, Inc. | 1.979B |
| Anixa Biosciences, Inc. | 63.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.407M |
| Total Expenses (Quarterly) | 5.407M |
| EPS Diluted (Quarterly) | -0.2034 |
| Earnings Yield | -132.9% |
| Normalized Earnings Yield | -95.23 |